Sanuwave Health (SNWV) Projected to Announce Earnings on Friday

Sanuwave Health (NASDAQ:SNWV) is projected to post its Q3 2026 resultson Friday, November 6th. Analysts expect the company to post earnings of $0.01 per share and revenue of $13.75 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

Sanuwave Health (NASDAQ:SNWV) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.05). The company had revenue of $9.74 million for the quarter, compared to the consensus estimate of $11.50 million. Sanuwave Health had a net margin of 32.38% and a return on equity of 1,728.10%.

Sanuwave Health Stock Performance

Shares of Sanuwave Health stock opened at $5.73 on Thursday. The company has a debt-to-equity ratio of 4.87, a current ratio of 1.28 and a quick ratio of 0.89. The firm has a market cap of $49.28 million, a P/E ratio of 24.71 and a beta of 1.47. The firm has a 50 day simple moving average of $4.89 and a 200 day simple moving average of $13.29. Sanuwave Health has a fifty-two week low of $3.92 and a fifty-two week high of $36.20.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Sanuwave Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 23rd. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $47.00.

About Sanuwave Health

SANUWAVE Health, Inc is a medical technology company focused on regenerative medicine and advanced wound-care solutions. The company develops and commercializes noninvasive devices that use extracorporeal shock wave technology to stimulate biological responses in damaged or difficult-to-heal tissue.

Its principal product is the dermaPACE system, which is designed to deliver acoustic shock waves to wound areas, including chronic diabetic foot ulcers. SANUWAVE has also pursued additional applications for its platform in areas such as orthopedic and soft-tissue healing, although the availability and regulatory status of specific products may vary by geography.

The company serves the wound-care and regenerative-medicine markets through commercial, clinical, and distribution activities in the United States and international markets.